5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy

Asthma Management: GINA/NAEPP Stepwise & SMART Therapy

Executive Summary: Asthma is a heterogeneous chronic inflammatory airway disorder characterized by episodic airflow obstruction, bronchial hyperresponsiveness, and variable respiratory symptoms. Modern clinical practice guidelines from the Global Initiative for Asthma (GINA) and the National Asthma Education and Prevention Program (NAEPP EPR-4) have fundamentally transformed asthma management by eliminating Short-Acting Beta-2 Agonist (SABA) monotherapy and establishing Inhaled Corticosteroid (ICS)-formoterol Single Maintenance and Reliever Therapy (SMART / MART) as the preferred standard of care (Track 1) across Steps 1 through 5.

---

1. The Paradigm Shift: Eliminating SABA Monotherapy

For decades, asthma guidelines recommended as-needed SABA monotherapy for intermittent asthma (Step 1). Landmark clinical trials (e.g., SYGMA 1, SYGMA 2, PRACTICAL, Novel START) demonstrated that SABA monotherapy confers substantial long-term risks:

• Beta-2 Receptor Downregulation: Frequent SABA use leads to rapid desensitization and downregulation of beta-2 adrenergic receptors on airway smooth muscle, decreasing bronchodilatory responsiveness.
• Rebound Bronchial Hyperresponsiveness: Unopposed SABA exposure increases airway hyperreactivity to allergens and viral triggers.
• Unaddressed Airway Inflammation: SABAs provide immediate symptomatic relief without suppressing underlying eosinophilic or T2-mediated airway inflammation. Patients relying on SABA monotherapy experience higher rates of life-threatening exacerbations and accelerated lung function decline.
• Mortality Risk: Dispensing $\ge 3$ SABA canisters (200 doses each) per year is associated with a significantly increased risk of emergency department visits and hospitalizations; dispensing $\ge 12$ canisters per year is directly linked to an increased risk of asthma-related death.

Consequently, GINA no longer recommends SABA monotherapy at any step of asthma management in adults and adolescents aged $\ge 12$ years. Every patient with asthma requires an ICS-containing regimen to treat underlying airway inflammation.

---

2. GINA Stepwise Management Architecture: Track 1 vs. Track 2

GINA stratifies asthma pharmacotherapy into two distinct treatment tracks. Track 1 is the preferred approach because it uses low-dose ICS-formoterol as the reliever across all steps, substantially reducing the risk of severe exacerbations compared to SABA relievers.

+---------------------------------------------------------------------------------------------------------+
|                                 GINA STEPWISE PHARMACOTHERAPY MATRIX                                    |
+------+--------------------------------------------------+-----------------------------------------------+
| STEP | TRACK 1 (Preferred: ICS-Formoterol Reliever)     | TRACK 2 (Alternative: SABA Reliever)          |
+------+--------------------------------------------------+-----------------------------------------------+
| 1    | As-needed low-dose ICS-formoterol                | Take low-dose ICS whenever SABA is taken      |
+------+--------------------------------------------------+-----------------------------------------------+
| 2    | As-needed low-dose ICS-formoterol                | Daily low-dose maintenance ICS + SABA PRN     |
+------+--------------------------------------------------+-----------------------------------------------+
| 3    | Low-dose ICS-formoterol maintenance and reliever | Daily low-dose ICS-LABA + SABA PRN            |
|      | (MART / SMART)                                   |                                               |
+------+--------------------------------------------------+-----------------------------------------------+
| 4    | Medium-dose ICS-formoterol maintenance and       | Daily medium/high-dose ICS-LABA + SABA PRN    |
|      | reliever (MART / SMART)                          |                                               |
+------+--------------------------------------------------+-----------------------------------------------+
| 5    | High-dose ICS-formoterol maintenance + add-on    | High-dose ICS-LABA + add-on LAMA, phenotypic  |
|      | LAMA, phenotypic biologic evaluation, + MART PRN | biologic evaluation, + SABA PRN               |
+------+--------------------------------------------------+-----------------------------------------------+

In-Depth Track 1: Single Maintenance and Reliever Therapy (SMART / MART)

In Track 1, the patient utilizes a single combination inhaler containing an ICS and formoterol for both daily maintenance (Steps 3–5) and acute symptom relief (Steps 1–5):

• Step 1–2 (Mild Asthma): As-needed low-dose ICS-formoterol taken whenever symptoms occur (no scheduled daily maintenance).
• Step 3 (Moderate Asthma): Low-dose ICS-formoterol maintenance (e.g., budesonide/formoterol 80/4.5 mcg or 160/4.5 mcg 1 puff BID or 2 puffs once daily) PLUS 1 puff as-needed for symptom relief.
• Step 4 (Moderate-to-Severe Asthma): Medium-dose ICS-formoterol maintenance (e.g., budesonide/formoterol 160/4.5 mcg 2 puffs BID) PLUS 1 puff as-needed for symptom relief.
• Step 5 (Severe Refractory Asthma): High-dose ICS-formoterol maintenance plus add-on Long-Acting Muscarinic Antagonist (LAMA; e.g., tiotropium Respimat 1.25 mcg 2 puffs once daily), phenotypic biomarker evaluation for targeted biologic therapy, and as-needed low-dose ICS-formoterol for symptom relief.

Pharmacology of Formoterol in SMART

Formoterol possesses unique pharmacodynamic and pharmacokinetic properties that make it the only LABA approved for SMART regimens:

1. Rapid Onset: Bronchodilation begins within 1 to 3 minutes, identical to albuterol, providing immediate relief during acute bronchospasm.
2. High Intrinsic Efficacy: Formoterol acts as a high-potency full/nearly full agonist at beta-2 receptors, unlike salmeterol (a partial agonist with slow onset of 15–30 minutes).
3. Long Duration: Provides sustained bronchodilation for 12 hours.
4. Maximum Daily Dose Ceiling: In SMART regimens, patients may take up to a total of 12 actuations per day of budesonide/formoterol 160/4.5 mcg (equivalent to a maximum of 54 mcg delivered formoterol or 72 mcg metered dose daily). If a patient requires $>12$ puffs in a 24-hour period, they must seek immediate emergency medical care.

Track 2: Alternative Strategy (Daily ICS + SABA Reliever)

Track 2 is considered an alternative when Track 1 is unavailable, cost-prohibitive, or when a patient is fully adherent, well-controlled, and exacerbation-free on their current conventional regimen:

• Step 1: As-needed SABA PLUS concomitant low-dose ICS whenever SABA is taken (either in a fixed combination like albuterol/budesonide [Airsupra] or two separate inhalers).
• Step 2: Daily low-dose maintenance ICS PLUS as-needed SABA.
• Step 3: Daily low-dose maintenance ICS-LABA (e.g., fluticasone propionate/salmeterol, mometasone/formoterol) PLUS as-needed SABA.
• Step 4: Daily medium- or high-dose maintenance ICS-LABA PLUS as-needed SABA.
• Step 5: High-dose ICS-LABA plus add-on LAMA, phenotypic biologic evaluation, PLUS as-needed SABA.

---

3. Inhaled Corticosteroid (ICS) Dosing Stratification

ICS dosing varies substantially across molecules and delivery devices. Pharmacists must recognize low, medium, and high daily dose thresholds for adults and adolescents ($\ge 12$ years):

Clinical Pearl: Extra-fine particle formulations (e.g., QVAR, Alvesco) achieve higher peripheral lung deposition with lower nominal microgram doses compared to standard particle formulations.

---

4. Assessment of Asthma Control & Step Titration Rules

Clinical Assessment of Symptom Control (Past 4 Weeks)

Evaluate four standardized domains:

1. Daytime asthma symptoms $>2$ times per week?
2. Any nighttime awakenings due to asthma?
3. SABA / reliever needed for symptoms $>2$ times per week?
4. Any activity limitation due to asthma?

Step-Up and Step-Down Protocols

• Sustained Step-Up: If asthma remains uncontrolled for $\ge 2\text{ to }3\text{ months}$, verify inhaler technique, medication adherence, environmental trigger exposure, and comorbid conditions (e.g., GERD, chronic rhinosinusitis, OSA) before escalating therapy by one step.
• Short-Term Step-Up: Increase reliever frequency or double ICS maintenance dose for 1–2 weeks during acute viral respiratory tract infections or seasonal allergen surges.
• Step-Down Therapy: Once asthma has remained well controlled for at least 3 consecutive months and lung function has stabilized:
  • Reduce ICS dose by 25% to 50% every 2 to 3 months.
  • Transition from BID to once-daily dosing where applicable.
  • Never completely discontinue ICS in adults or adolescents due to immediate risk of severe flare-ups.

---

5. Asthma Exacerbation Action Plan

Every ambulatory patient with asthma should possess a written, personalized Asthma Action Plan based on symptoms and Peak Expiratory Flow (PEF) percentage of personal best:

+---------------------------------------------------------------------------------------------------------+
|                                 PERSONAL ASTHMA ACTION PLAN ZONES                                       |
+-------------+---------------------+-------------------------------+-------------------------------------+
| ZONE        | PEF (% Personal Best)| CLINICAL SYMPTOMS             | ACTION REQUIRED                     |
+-------------+---------------------+-------------------------------+-------------------------------------+
| GREEN ZONE  | 80% to 100%         | No cough, wheeze, or dyspnea; | Continue routine baseline           |
| (Safety)    |                     | normal activity & sleep       | controller maintenance therapy      |
+-------------+---------------------+-------------------------------+-------------------------------------+
| YELLOW ZONE | 50% to 79%          | Cough, mild wheezing, chest   | Increase reliever frequency;        |
| (Caution)   |                     | tightness, nighttime waking   | Initiate oral prednisone burst:     |
|             |                     |                               | 40-50 mg daily for 5-7 days (adults)|
+-------------+---------------------+-------------------------------+-------------------------------------+
| RED ZONE    | <50%                | Severe shortness of breath,   | Take 4-8 puffs reliever + 50 mg     |
| (Medical    |                     | speech in single words,       | prednisone immediately; call 911 /  |
| Emergency)  |                     | rib retractions, cyanosis     | proceed to emergency department     |
+-------------+---------------------+-------------------------------+-------------------------------------+

Outpatient Systemic Corticosteroid Burst Protocols

• Prednisone (or Prednisolone): 40 to 50 mg orally once daily for 5 to 7 days in adults (1–2 mg/kg/day max 40–50 mg for 3–5 days in children).
• Tapering Principle: Courses of oral corticosteroids lasting $\le 7\text{ to }10\text{ days}$ do not require a dose taper, as hypothalamic-pituitary-adrenal (HPA) axis suppression is negligible over this brief duration. Abrupt cessation after 5–7 days is safe and minimizes cumulative steroid toxicity.

---

6. Severe Asthma Biologics & Phenotypic Precision Selection

Approximately 5% to 10% of asthma patients have severe refractory disease (Step 5) uncontrolled despite high-dose ICS-LABA and add-on LAMA. Selection of add-on monoclonal antibody biologics is guided by precision inflammatory phenotyping:

1. Allergic Phenotype (Anti-IgE)

• Omalizumab (Xolair): Humanized IgG1k mAb that selectively binds to circulating free IgE, preventing binding to high-affinity Fc$\epsilon$RI receptors on mast cells and basophils.
  • Biomarker Criteria: Baseline serum total IgE 30–700 IU/mL (or up to 1,300 IU/mL) AND positive skin test or in vitro reactivity to a perennial aeroallergen.
  • Dosing: Subcutaneous (SC) every 2 or 4 weeks; dose determined by baseline body weight (kg) and pre-treatment total serum IgE level.
  • Black Box Warning: Anaphylaxis (can occur after the first dose or $>1$ year into therapy; delayed onset $>24$ hours possible). Patients must be observed post-injection and co-prescribed an epinephrine auto-injector.

2. Eosinophilic Phenotype (Anti-IL-5 / Anti-IL-5R / Anti-IL-4Rα)

Characterized by blood eosinophils $\ge 150\text{ to }300\text{ cells/}\mu\text{L}$, elevated sputum eosinophils, and elevated Fractional Exhaled Nitric Oxide (FeNO $\ge 25\text{ ppb}$):

• Mepolizumab (Nucala): Anti-IL-5 mAb that binds circulating IL-5 cytokine. Dose: 100 mg SC every 4 weeks.
• Reslizumab (Cinqair): Anti-IL-5 mAb that binds circulating IL-5 cytokine. Dose: 3 mg/kg IV infusion over 20–50 minutes every 4 weeks. Black Box Warning: Anaphylaxis (~0.3%); requires IV infusion suite monitoring.
• Benralizumab (Fasenra): Anti-IL-5 Receptor alpha (IL-5R$\alpha$) mAb. Binds directly to IL-5R$\alpha$ on eosinophils and basophils, recruiting Natural Killer (NK) cells via Fc$\gamma$RIIIa to induce Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). Produces near-complete depletion of blood and tissue eosinophils within 24 hours. Dose: 30 mg SC every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
• Dupilumab (Dupixent): Anti-IL-4 Receptor alpha (IL-4R$\alpha$) mAb. Blocks the shared IL-4R$\alpha$ subunit, inhibiting downstream signaling of both IL-4 and IL-13 (dual Th2 pathway inhibition). Dose: 400 mg SC loading dose then 200 mg every 2 weeks, or 600 mg SC loading dose then 300 mg every 2 weeks (preferred if oral steroid-dependent or with comorbid severe atopic dermatitis). Adverse Effect: Transient blood hypereosinophilia, injection site reactions, conjunctivitis.

3. Broad / Non-Eosinophilic / Epithelial Alarmin Phenotype (Anti-TSLP)

• Tezepelumab (Tezspire): Anti-Thymic Stromal Lymphopoietin (anti-TSLP) mAb. Blocks TSLP, an upstream epithelial cytokine (alarmin) released in response to viruses, allergens, pollutants, and mechanical trauma.
  • Mechanism: Acts at the top of the inflammatory cascade, suppressing both T2-high (eosinophilic/allergic) and T2-low (non-eosinophilic/neutrophilic) inflammation.
  • Biomarker Criteria: No baseline biomarker restrictions; approved for severe asthma regardless of blood eosinophils, FeNO, or allergic sensitization.
  • Dosing: 210 mg SC every 4 weeks.